vetIQure is an innovation in oncology care and its unique and patented TSE technology ensures reversible electroporation designed for a safe and easy tumour treatment that spares the healthy tissue.
The dynamic and multi-dimensional electric pulse enhances traditional chemotherapy with a tumour- specific and controlled distribution of the electric field, which enables the coverage of the treated area. It increases the cells’ membrane permeability allowing cytotoxic drugs to enter the tumour cell.
TSE is designed to activate the immune system through the apoptosis and release of a specific tumour antigen.
TSE also makes it possible to treat non-responsive tumours and tumours in sensitive locations.
Using the customised adjustable hand-held probe, the veterinarian can choose to treat both smaller and larger areas using the same probe which also improves the ability to treat hard-to-reach locations.
The TSE technology is well-suited to treat tumours in sensitive areas where surgery is not possible such as head and neck tumours. It can be used as a primary treatment or in combination with surgery to shrink the tumour and/or treat unclean margins.
The therapy begins by administrating a cytotoxic drug to the patient either intravenously or intra-tumorally.
By treating the tumour cells with TSE pulses, the cell membranes becomes reversibly permeable allowing the cytotoxic drug to enter the cells.
After each treatment cycle with TSE the cells returns to a none-permeable state. The cytotoxic drug is trapped inside the cells and create apoptosis (programmed cell death).